Yu-Cheng Kuo

Also affiliated with China Medical University, Sam Houston State University, China Medical University Hospital, Taipei Medical University, National Cheng Kung University

MedicineBiochemistry, Genetics and Molecular BiologyComputer Science

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “In vivo Pharmacokinetic and Anticancer Studies of HH-N25, a Selective Inhibitor of Topoisomerase I, and Hormonal Signaling for Treating Breast Cancer”.

In vivo Pharmacokinetic and Anticancer Studies of HH-N25, a Selective Inhibitor of Topoisomerase I, and Hormonal Signaling for Treating Breast Cancer

Journal of Inflammation Research(2021)10.2147/jir.s329401

N/A

0DataRank · unranked

28 citations

Yu-Cheng Kuo, Maryam Rachmawati Sumitra, Alexander T.H. Wu, Hsu‐Shan Huang, Bashir Lawal

BC-N102 suppress breast cancer tumorigenesis by interfering with cell cycle regulatory proteins and hormonal signaling, and induction of time-course arrest of cell cycle at G1/G0 phase

International Journal of Biological Sciences(2021)10.7150/ijbs.62808

N/A

0DataRank · unranked

13 citations

Yu-Cheng Kuo, Alexander T.H. Wu, Hsu‐Shan Huang, Bashir Lawal